OCCURRENCE AND ANTIBIOGRAM STUDIES OF PSEUDOMONAS AERUGINOSA FROM URINARY TRACT INFECTION
DOI:
https://doi.org/10.71000/spjpfw04Keywords:
Anti-Bacterial Agents; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Tract Infections; UrineAbstract
Background: Pseudomonas aeruginosa is an important opportunistic pathogen associated with complicated and healthcare-associated urinary tract infections. Its intrinsic resistance, capacity to acquire additional resistance mechanisms, and persistence in moist clinical environments can limit treatment options and increase the risk of therapeutic failure. Local surveillance is therefore essential because antimicrobial susceptibility patterns vary across institutions and geographical areas. Reliable regional data can support empirical treatment, antimicrobial stewardship, and timely selection of effective antipseudomonal therapy for affected patients.
Objective: The study determined the occurrence of P. aeruginosa in urine specimens from patients with suspected urinary tract infection and assessed the antimicrobial susceptibility profile of confirmed isolates.
Methods: A multicentre, laboratory-based cross-sectional study processed 565 clean-catch midstream urine specimens collected from four public and private laboratories in Punjab, Pakistan, between January and March 2020. Specimens were cultured on cetrimide agar, and suspected isolates were identified through colony morphology, Gram staining, motility, and biochemical testing. Antimicrobial susceptibility to 14 agents was assessed by the modified Kirby–Bauer disc diffusion method using CLSI 2019 interpretive criteria. Frequencies and percentages were calculated.
Results: Fifty-two specimens were positive for confirmed P. aeruginosa, giving an occurrence of 9.2%. Of the confirmed isolates, 30 (57.7%) were obtained from females and 22 (42.3%) from males. Susceptibility was highest to colistin at 100%, followed by tobramycin at 88.5%, meropenem at 78.8%, piperacillin–tazobactam and cefepime at 73.1% each, amikacin at 71.2%, imipenem at 69.2%, and gentamicin at 67.3%. Resistance was highest to amoxicillin–clavulanate at 94.2% and ceftriaxone at 82.7%, followed by levofloxacin at 53.8%, ofloxacin at 50.0%, ciprofloxacin at 46.2%, and ceftazidime at 44.2%.
Conclusion: P. aeruginosa showed substantial variation in antimicrobial susceptibility, supporting culture-guided therapy and regular local antibiogram surveillance. Rational prescribing and strengthened antimicrobial stewardship remain necessary to limit further resistance and preserve effective treatment options.
Keywords: Anti-Bacterial Agents; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Tract Infections; Urine
References
Rahimzadeh M, Shahbazi S, Sabzi S, Habibi M, Asadi Karam MR. Antibiotic resistance and genetic diversity among Pseudomonas aeruginosa isolated from urinary tract infections in Iran. Future Microbiol. 2023;18:1171-83.
Requena-Cabello H, Rodríguez-Guerrero E, Expósito-Ruiz M, Navarro-Marí JM, Gutierrez-Fernandez J. Antibiotic resistances of Pseudomonas aeruginosa and Acinetobacter baumannii in urine cultures: experience in a hospital of Southeast Spain. Apmis. 2024;132(2):100-11.
Do DV, Tran TTH, Tran TL, Nguyen QD, Truong TP, Nguyen TTM, et al. Antimicrobial resistance in complicated urinary tract infections: A retrospective study from a rehabilitation centre in a resource-limited setting. J Glob Antimicrob Resist. 2026;49:72-9.
Fatima A, Rizvi M, Sajjad M, Gohar H, Iffat W, Bushra R. Antimicrobial resistance pattern of Uro-Pathogens emphasizing non-lactose fermenting gram negative bacilli. J Pak Med Assoc. 2024;74(4):661-5.
Riquelme-Bravo E, Molina-Cano M, Domínguez-Jiménez MC, Poliakova-Mazneva Y, March-Roselló GA, Lorenzo-Vidal B, et al. Antimicrobial susceptibility profile of multidrug-resistant uropathogens in community-acquired urinary tract infections in Spain: A multicenter GEIAP-SEIMC study. Enferm Infecc Microbiol Clin (Engl Ed). 2026;44(6):503181.
Kang JS, Moon C, Mun SJ, Lee JE, Lee SO, Lee S, et al. Antimicrobial Susceptibility Trends and Risk Factors for Antimicrobial Resistance in Pseudomonas aeruginosa Bacteremia: 12-Year Experience in a Tertiary Hospital in Korea. J Korean Med Sci. 2021;36(43):e273.
Farjana NE, Islam MA, Zerin T, Begum MA. Bacterial association in urinary tract infection and their drug resistance among patients in Rajshahi, Bangladesh. International Journal of Community Medicine and Public Health. 2021;8(5):2144.
Mahjabin S, Rahman R, Munni UR, Mobin ME, Pyash AS, Shoshi HR. Bacterial profile and antibiotic resistance pattern of uropathogens isolated from patients with complicated urinary tract infections in a tertiary care hospital in Dhaka, Bangladesh. BMC Infect Dis. 2025;25(1):1538.
Devraj A, Chand U, Singh A, Kushawaha PK. Chitosan and naringenin-coated silver nanoparticles as a nanoplatform against drug-resistant uropathogens. Braz J Microbiol. 2026;57(1).
Riedel S, Halls J, Dutta S, Toraskar N, Lemon J, Carter K, et al. Clinical evaluation of the acuitas® AMR gene panel for rapid detection of bacteria and genotypic antibiotic resistance determinants. Diagn Microbiol Infect Dis. 2021;100(4):115383.
de Sousa T, Carvalho M, Beyrouthy R, Bonnet R, Martins Â, Hebraud M, et al. Decoding Pseudomonas aeruginosa: Genomic insights into adaptation, antibiotic resistance, and the enigmatic role of T6SS in interbacterial dynamics. Microb Pathog. 2024;196:106932.
Trześniewska-Ofiara Z, Mendrycka M, Woźniak-Kosek A. Drug susceptibility of uropathogens isolated from patients treated at the Mazovian Specialized Hospital in Radom. Acta Biochim Pol. 2025;72:14082.
Wang Z, Li J, Li Y, Chen Z, Ren E, Zhang P. Emergence of a multidrug-resistant Pseudomonas fulva clinical isolate co-harboring tmexCD3-toprJ3, bla (OXA-1), and bla (IMP-45) on a transferable megaplasmid. Front Cell Infect Microbiol. 2026;16:1722020.
Fleck RC, Gorodyna O, Zhou H, Bryant H, Gadjeva M, Shea AE. Emerging pathogens in urinary tract infections: virulence and phenotypic characterization of Pseudomonas aeruginosa strains. mSphere. 2026;11(6):e0015126.
Kobayashi K, Takahashi S, Yasuda M, Miyazaki J, Wada K, Matsumoto M, et al. Fourth national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from patients with complicated urinary tract infections. J Infect Chemother. 2024;30(7):579-89.
Nguyen QH, Nguyen TS, Tran TTT, Do BN, Bui TS, Bui TT, et al. Genomic characterization of an extensively drug-resistant high-risk Pseudomonas aeruginosa ST1971 harbouring tmexCD2-toprJ2 from a Vietnamese patient with urinary tract infection. J Glob Antimicrob Resist. 2026;48:127-30.
Ebrahim H, Haldenby S, Moore MP, Dashti AA, Floyd RV, Fothergill JL. Genotypic and phenotypic analyses of two distinct sets of Pseudomonas aeruginosa urinary tract isolates. J Med Microbiol. 2025;74(2).
Mohamed MS, Abd Alfadil NA, Gibril SI, Elsaman T, Mohamed MA. Identification and 16s rRNA Gene Sequence Analysis of Multidrug-Resistant Pseudomonas Aeruginosa in Paper Currency Notes. 2020.
Pournajafi A. Investigation of the Prevalence of CTX-M-1 Beta-Lactamase Gene in Pseudomonas Aeruginosa Strains Isolated From Urinary Tract Infections in Zanjan Hospitals, Iran. 2020.
Shaaban MT, Abdel-Raouf M, Zayed M, Emara MA. Microbiological and molecular studies on a multidrug-resistant Pseudomonas aeruginosa from a liver transplant patient with urinary tract infection in Egypt. BMC Microbiol. 2024;24(1):184.
Mousa MMA, Abou-Dobara MI, El-Zahed MM, El-Sherif ME, Saleh HH. Molecular detection and ultrastructure characterization of some drug-resistant Gram-negative bacteria isolated from bladder cancer patients. BMC Microbiol. 2025;26(1):57.
Abbott IJ, Anderson CRB, van Gorp E, Wallis SC, Roberts JA, Meletiadis J, et al. Oral ciprofloxacin biofilm activity in a catheter-associated urinary tract infection model. J Antimicrob Chemother. 2025;80(2):413-26.
Jurado-Martín I, Sainz-Mejías M, McClean S. Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. International Journal of Molecular Sciences. 2021;22(6):3128.
Thacker B, Madan S, Pethani D, Nathwani P, Shah B, Shah K, et al. Pyelonephritis Caused by Pseudomonas aeruginosa: From Treatable Infection to Therapeutic Dead-End, Rescued by an Investigational Antibiotic. Microb Drug Resist. 2026;32(5):177-81.
Babidhan R, Lewis A, Atkins C, Jozefczyk NJ, Nemecek BD, Montepara CA, et al. Safety and efficacy of cefiderocol for off-label treatment indications: A systematic review. Pharmacotherapy. 2022;42(7):549-66.
Pan F, Altenried S, Scheibler S, Anthis AHC, Ren Q. Specific capture of Pseudomonas aeruginosa for rapid detection of antimicrobial resistance in urinary tract infections. Biosens Bioelectron. 2023;222:114962.
Kim JA, Noh HS, Kim JH. Trends in antimicrobial resistance of major gram-negative uropathogens, 2016-2024: A single center retrospective study. Investig Clin Urol. 2026;67(4):383-91.
Garvey M, McMurray C, Holden E, Walker J. Waterborne transmission of Pseudomonas aeruginosa. Decontamination in Hospitals and Healthcare: Elsevier; 2020. p. 101-14.
Murri R, Sacco E. What place does ceftolozane/tazobactam have in the treatment of complicated urinary-tract infections? Expert Opin Pharmacother. 2021;22(11):1377-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Nadia Saddique, Nosheen, Nafeesa Safdar , Wajiha Kanwal , Sobia Rizwan, Atiq Ur Rehman, Muhammad Sulaman Fazil , Abdul Rehman Saddiq (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
